文献速递糖尿病垂体与肾上腺疾病

钠-葡萄糖协同转运蛋白2抑制剂对糖尿病合并晚期慢性肾脏病患者心血管和肾脏结局的影响

Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease.
PubMed 文献 · Diabetologia · 2024-08-29

这项回顾性队列研究利用两家机构的病历数据,纳入2016年1月1日至2021年12月31日期间处方SGLT2i且后续两次eGFR<30 ml/min per 1.73 m²的2型糖尿病患者,比较继续使用与停用SGLT2i的结局。经逆概率治疗加权后,继续使用与主要不良心血管事件复合终点风险显著降低相关(HR 0.65 [95% CI 0.43, 0.99]),eGFR下降≥50%和全因住院风险也显著降低,安全性结局无显著差异。

要点

  • 继续使用SGLT2i与主要不良心血管事件复合终点风险显著降低相关(HR 0.65 [95% CI 0.43, 0.99])。
  • 继续使用SGLT2i与eGFR下降≥50%风险(SHR 0.58 [95% CI 0.42, 0.81])和全因住院风险(SHR 0.77 [95% CI 0.64, 0.94])显著降低相关。
  • 两组安全性结局无显著差异;继续组随访末血红蛋白显著更高(114.6 g/l vs 110.4 g/l,差值4.12 g/l;p=0.047)。

核心结论

  • 在已接受SGLT2i治疗的慢性肾脏病患者中,eGFR降至30 ml/min per 1.73 m²或以下后继续使用SGLT2i,与停用相比心血管和肾脏事件风险更低。
  • 作者认为,应考虑在整个慢性肾脏病病程中继续使用SGLT2i以优化患者结局。

研究设计与样本

  • 这是一项回顾性队列研究,利用两家机构的病历数据。
  • 纳入2016年1月1日至2021年12月31日期间处方SGLT2i、且后续至少间隔90天两次记录eGFR<30 ml/min per 1.73 m²的2型糖尿病患者。
  • 以eGFR首次达到低于30 ml/min per 1.73 m²的日期为索引日期,按索引日期后是否使用SGLT2i分为继续组(337例)和停用组(358例)。
  • 采用逆概率治疗加权(IPTW)以减少混杂。

主要发现

  • 经IPTW后,继续使用SGLT2i与主要不良心血管事件复合终点风险显著低于停用相关(HR 0.65 [95% CI 0.43, 0.99]),主要归因于随访期间心肌梗死风险降低(亚分布HR [SHR] 0.43 [95% CI 0.21, 0.89])。
  • 继续组eGFR下降≥50%的发生率显著低于停用组(SHR 0.58 [95% CI 0.42, 0.81])。
  • 继续组全因住院发生率显著低于停用组(SHR 0.77 [95% CI 0.64, 0.94])。
  • 两组所研究的安全性结局均无显著差异。
  • 随访末继续组血红蛋白水平显著高于停用组(114.6 g/l vs 110.4 g/l,差值4.12 g/l;p=0.047)。

临床怎么用

  • 作者认为,应考虑在整个慢性肾脏病病程中继续使用SGLT2i以优化患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Although the benefits of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in chronic kidney disease (CKD) are well established, the effects of these therapeutic agents in patients with advanced CKD are less certain. We hypothesised that the continued use of these drugs, even when renal function deteriorates to stage 4 CKD or worse, is safe and associated with improved cardiorenal survival. METHODS: This is a retrospective cohort study utilising data from medical records from two institutions. All patients with type 2 diabetes mellitus who were prescribed an SGLT2i between 1 January 2016 and 31 December 2021, who subsequently had eGFR <30 ml/min per 1.73 m2 recorded on two occasions at least 90 days apart, were identified. The date on which the eGFR first reached any level less than 30 ml/min per 1.73 m2 was defined as the index date. Individuals were then categorised into the SGLT2i continuation group or the discontinuation group according to the use of SGLT2i after the index date. Inverse probability of treatment weighting (IPTW) was performed to minimise confounding. Outcomes of interest included heart failure outcomes, cardiovascular outcomes, renal outcomes and safety outcomes. RESULTS: According to the eligibility criteria, 337 patients in the continuation group and 358 in the discontinuation group were identified. After IPTW, continuation of SGLT2i use was associated with significantly lower risks of the composite of major adverse cardiovascular events compared with discontinuation of SGLT2i use (HR 0.65 [95% CI 0.43, 0.99]), largely driven by reduced risk of myocardial infarction during follow-up (subdistribution HR [SHR] 0.43 [95% CI 0.21, 0.89]). The incidences of an eGFR decline of 50% or more (SHR 0.58 [95% CI 0.42, 0.81]) and all-cause hospital admission (SHR 0.77 [95% CI 0.64, 0.94]) were also significantly lower in the continuation group. None of the studied safety outcomes were significantly different when comparing the two groups. Blood haemoglobin levels were significantly higher in the continuation group at the end of follow-up (114.6 g/l vs 110.4 g/l, with a difference of 4.12 g/l; p=0.047). CONCLUSIONS/INTERPRETATION: In patients with CKD who were treated with an SGLT2i, continuation of SGLT2i use after eGFR declined to 30 ml/min per 1.73 m2 or less was associated with lower risks of cardiovascular and renal events compared with discontinuation of SGLT2i use. Continued use of SGLT2i throughout the course of CKD should be considered to optimise patient outcomes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lin DS, Lee JK, Huang KC, et al. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease. Diabetologia. 2024. PMID: 39207471. doi:10.1007/s00125-024-06257-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。